ConductScience.org, home

Paper2201397

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

Shearer RJ and 6 others. Br J Cancer, 1990. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Aromatase inhibition in advanced prostatic cancer: preliminary communication. Papers, record 2201397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2201397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
PubMed
Journal
Br J Cancer
PubMed
Year
1990
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.45
iCite
Revised in PubMed
2019-05-15
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shearer RJR J
2Davies JHJ H
3Dowsett MM
4Malone PRP R
5Hedley AA
6Cunningham DD
7Coombes RCR C

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aromatase InhibitorsMajor topic
Prostatic NeoplasmsMajor topic
Aged
Aged, 80 and over
Androstenedione
Antineoplastic Agents
Clinical Trials as Topic
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15963388A new oral progestational steroid effective in treating prostatic cancer.Trans Am Assoc Genitourin Surg1966https://conductscience.org/library/papers/5963388PubMed
2109413Actions of estrogen in the male.Invest Urol1979https://conductscience.org/library/papers/109413PubMed
37336466Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.Steroids1981https://conductscience.org/library/papers/7336466PubMed
46180250Failure of human benign prostatic hyperplasia to aromatise testosterone.J Steroid Biochem1982https://conductscience.org/library/papers/6180250PubMed
56827685Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma.J Urol1983https://conductscience.org/library/papers/6827685PubMed
66238616Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.Br J Cancer1984https://conductscience.org/library/papers/6238616PubMed
73358910The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.Br J Cancer1988https://conductscience.org/library/papers/3358910PubMed
83155636Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.Br Med J (Clin Res Ed)1985https://conductscience.org/library/papers/3155636PubMed
94084734Is delayed treatment justified in carcinoma of the prostate?Br J Urol1985https://conductscience.org/library/papers/4084734PubMed
102431401Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia.Prostate1986https://conductscience.org/library/papers/2431401PubMed
112433507Aromatase inhibitors and benign prostatic hyperplasia.J Steroid Biochem1986https://conductscience.org/library/papers/2433507PubMed
123815384Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.Cancer Res1987https://conductscience.org/library/papers/3815384PubMed
133567487Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.Br J Urol1987https://conductscience.org/library/papers/3567487PubMed
1461502774-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.Lancet1984https://conductscience.org/library/papers/6150277PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
7680986Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.Drugs1993https://conductscience.org/library/papers/7680986PubMed
1637664Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.Br J Cancer1992https://conductscience.org/library/papers/1637664PubMed
1493356Aromatase inhibitors in malignant diseases of aging.Drugs Aging1992https://conductscience.org/library/papers/1493356PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP19A11588PubTator's text mininghttps://conductscience.org/library/genes/1588

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2201397

GET https://conductscience.org/api/papers/v1/2201397/authors